Whitepaper , Human ADME

Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies

Home
Resources
Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies

Overview

We are a leading provider of 14C-enabled drug development programs, successfully conducting over 350 human ADME and other radiolabeled programs to date. Learn about Synthesis-to-Clinic®.

Download

First name

Last name

Company name

Job title

Phone

City

Country

Do you want to opt into updates on news and info?

Yes, please opt me in for updates

No, I don't wish to receive updates

Your challenges. Our solutions.

Learn more about our expertise in human ADME studies.

Human ADME, Regulatory

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

By: Dr. Adam Robinson-Miller Read More

Humanity can't afford to wait, so neither can we.

Let's talk

Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies

Download

Your challenges. Our solutions.

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

ISSX 2022: A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes

Human ADME Capabilities

Synthesis-to-Clinic®: A streamlined approach to 14C human ADME studies

Download

Share

Your challenges. Our solutions.

Assessing the Impact of the Approved FDA Guidance on Human Mass Balance Studies: How ADME programs will proceed in 2024 and beyond

More about our human ADME capabilities

ISSX 2022: A Decade of Human ADME at Quotient Sciences: Reviewing Key Study Design Variables and Outcomes

Human ADME Capabilities